LP 00A
Alternative Names: LP-00ALatest Information Update: 30 Jan 2026
At a glance
- Originator LongBio Pharma
- Class Antiallergics; Antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypersensitivity
Most Recent Events
- 03 Dec 2025 Preclinical trials in Hypersensitivity in China (unspecified route)